Related references
Note: Only part of the references are listed.Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline
Nimish A. Mohile et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma
Jiang Xiulin et al.
Aging-US (2022)
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
Catia Monteiro et al.
NATURE MEDICINE (2022)
Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study
Louis Garnier et al.
ONCOLOGIST (2022)
Bioinformatics analysis of LMAN1 expression, clinical characteristics, and its effects on cell proliferation and invasion in glioma
Qiu Du et al.
BRAIN RESEARCH (2022)
Differences of macrophages in the tumor microenvironment as an underlying key factor in glioma patients
Yangyang Wang et al.
FRONTIERS IN IMMUNOLOGY (2022)
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
Michael Weller et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort
Vincent Esteyrie et al.
ONCOLOGIST (2021)
Oxysterol binding protein-like 3 (OSBPL3) is a novel driver gene that promotes tumor growth in part through R-Ras/Akt signaling in gastric cancer
Qingjiang Hu et al.
SCIENTIFIC REPORTS (2021)
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study
Martin J. van den Bent et al.
LANCET ONCOLOGY (2021)
S100A gene family: immune-related prognostic biomarkers and therapeutic targets for low-grade glioma
Yu Zhang et al.
AGING-US (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
ESPL1 Is a Novel Prognostic Biomarker Associated With the Malignant Features of Glioma
Zhendong Liu et al.
FRONTIERS IN GENETICS (2021)
Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma
Apeng Chen et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Discovery of a dual inhibitor of NQO1 and GSTP1 for treating glioblastoma
Kecheng Lei et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Identification of glycogene-type and validation of ST3GAL6 as a biomarker predicts clinical outcome and cancer cell invasion in urinary bladder cancer
Sumiya Dalangood et al.
THERANOSTICS (2020)
CDKN2A HOMOZYGOUS DELETION IS A STRONG ADVERSE PROGNOSIS FACTOR IN DIFFUSE MALIGNANT IDHMUTANT GLIOMAS
R. Appay et al.
NEURO-ONCOLOGY (2019)
LncRNA ST3Gal6-AS1/ST3Gal6 axis mediates colorectal cancer progression by regulating α-2,3 sialylation via PI3K/Akt signaling
Jialei Hu et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Hypoxia and serum deprivation induces glycan alterations in triple negative breast cancer cells
Amanda P. B. Albuquerque et al.
BIOLOGICAL CHEMISTRY (2018)
撤稿声明: Inactivation of the Quinone Oxidoreductases NQO1 and NQO2 Strongly Elevates the Incidence and Multiplicity of Chemically Induced Skin Tumors (Retraction of Vol 70, Pg 1006, 2010)
Jun Shen et al.
CANCER RESEARCH (2018)
Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma
Xin Hu et al.
NEURO-ONCOLOGY (2017)
Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial
Hendrikus J. Dubbink et al.
NEURO-ONCOLOGY (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Identification of Patients with Recurrent Glioblastoma Who May Benefit from Combined Bevacizumab and CCNU Therapy: A Report from the BELOB Trial
Lale Erdem-Eraslan et al.
CANCER RESEARCH (2016)
Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function
Paul R. Gielen et al.
NEURO-ONCOLOGY (2016)
Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
Jan C. Buckner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Empirical extensions of the lasso penalty to reduce the false discovery rate in high-dimensional Cox regression models
Nils Ternes et al.
STATISTICS IN MEDICINE (2016)
Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas
Aurelie Kamoun et al.
NATURE COMMUNICATIONS (2016)
Bootstrap Enhanced Penalized Regression for Variable Selection with Neuroimaging Data
Samantha V. Abram et al.
FRONTIERS IN NEUROSCIENCE (2016)
ATCT-16CODEL (ALLIANCE-N0577; EORTC-26081/2208; NRG-1071; NCIC-CEC-2): PHASE III RANDOMIZED STUDY OF RT VS. RT + TMZ VS. TMZ FOR NEWLY DIAGNOSED 1p/19q-CODELETED ANAPLASTIC GLIOMA. ANALYSIS OF PATIENTS TREATED ON THE ORIGINAL PROTOCOL DESIGN
Kurt Jaeckle et al.
NEURO-ONCOLOGY (2015)
Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations
Dominique Figarella-Branger et al.
NEURO-ONCOLOGY (2014)
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas
Justin S. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Modified expression of Mts1/S100A4 protein in C6 glioma cells or surrounding astrocytes affects migration of tumor cells in vitro and in vivo
Keizo Takenaga et al.
NEUROBIOLOGY OF DISEASE (2007)
1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment
Mathilde C. M. Kouwenhoven et al.
EUROPEAN JOURNAL OF CANCER (2006)
Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
Gregory Cairncross et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Share Paper
